
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is expected to continue its upward trend in revenue growth, especially with the success of its Panorama and Horizon tests in the women's health sector, and the potential increase in revenue from its Signatera test for oncology minimal residual disease testing. The company has also shown impressive growth in its Signatera MRD business, with a record increase in test units and a projected expansion into 20+ solid tumor cancer states and 5 types of organ transplants. Additionally, with its ongoing development of a blood-based cancer detection test and its potential for companion diagnostic approvals, Natera is well-positioned to maintain its market leader status in the genetic testing industry.
Bears say
Natera is a diagnostic and research company with a diverse product portfolio, but the negative outlook is based on the potential for competition and regulatory challenges in the NIPT and liquid biopsy markets, reliance on lab partnerships, and the potential for pricing pressures due to Medicaid and Medicare coverage decisions. Additionally, the company's reliance on lab partnerships and potential ethical concerns surrounding genetic testing could also impact demand for its products. Overall, challenges in key markets and potential regulatory hurdles may limit the company's growth and profitability in the future.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares